Essais liés12clinical trials
VilleKragujevaclocalisation
PaysSerbialocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06540833

Ouvrir le site du centre

Essais cliniques associés

12
MoléculeIndication / populationPhaseNCTTitreStatut
ACP-204 Alzheimer Phase 2/3 NCT06159673 ACP-204 in Adults With Alzheimer's Disease Psychosis RECRUITING
KarXT Alzheimer Phase 3 NCT06585787 A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) RECRUITING
ITI-1284 Alzheimer Phase 2 NCT06540833 A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease RECRUITING
Efgartigimod IV Myasthénie Phase 3 NCT06298552 ADAPT SERON — A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis ACTIVE_NOT_RECRUITING
Litifilimab Lupus Phase 2/3 NCT05531565 AMETHYST — A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus ACTIVE_NOT_RECRUITING
Eptinezumab Migraine Phase 3 NCT05897320 PROSPECT-1 — A Study of Eptinezumab in Pediatric Participants With Episodic Migraine RECRUITING
Eptinezumab Migraine Phase 3 NCT05164172 REJOIN — A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine RECRUITING
Eptinezumab Migraine Phase 3 NCT04965675 PROSPECT-2 — A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine RECRUITING
LP352 Épilepsie Phase 3 NCT06660394 A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) RECRUITING
LP352 Épilepsie Phase 3 NCT06719141 A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) ACTIVE_NOT_RECRUITING
Ocrelizumab SEP Phase 3 NCT04035005 O'HAND — A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis ACTIVE_NOT_RECRUITING
Ponesimod SEP Phase 3 NCT03232073 Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis COMPLETED